TNGX MEXC RealStocks
Own real TNGX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-18 23:35:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Tango Therapeutics, Inc. (TNGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $21.89, with a market capitalization of $4.10B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.69 to $34.39. This page covers its latest market performance, valuation, price trends and company information.
$4.10B | |
$22.03 | |
$22.74 | |
$21.30 | |
$22.11 | |
2.38M | |
3.44M | |
-- | |
$34.39 | |
$7.69 | |
-- | |
2026-09-30 |
Tango Therapeutics, Inc. (TNGX) is trading at $21.89 in after-hours trading as of 2026-11-18 21:55:00, down 0.01% ($0.00) from the regular-session close of $21.89.
After-hours trading shows how investors are pricing TNGX after the regular session closes. The current after-hours price is near the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Tango Therapeutics, Inc. (TNGX) moved from $22.74 to $21.89, representing a decline of 3.75% ($0.85).
The stock traded between $21.12 and $26.41 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 2.97 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 53.2%
TNGX is currently trading at $21.89, placing it 53.2% of the way from its 52-week low of $7.69 to its 52-week high of $34.39. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 137 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tango Therapeutics, Inc. (TNGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TNGX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TNGX shares and USD.
TNGX Shares to USD
1.00 TNGX shares = 21.888 USD
Calculations are estimates based on the latest available price and are for reference only.